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A B S T R A C T
Background
Among people who have suIered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it
is estimated that about 11 people per 100 with traumatic brain injury die.
Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately,
restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury.
Objectives
To assess the eIects of indomethacin for adults with severe traumatic brain injury.
Search methods
We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We
also screened reference lists and conference abstracts, and contacted experts in the field.
Selection criteria
Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with
severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery.
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Data collection and analysis
Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods.
Main results
We identified no eligible studies for this review, either completed or ongoing.
Authors' conclusions
We found no studies, either completed or ongoing, that assessed the eIects of indomethacin in controlling intracranial hypertension
secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the eIects of indomethacin on intracranial
pressure, mortality rates, quality of life, disability or adverse eIects.
This absence of evidence should not be interpreted as evidence of no eIect for indomethacin in controlling intracranial hypertension
secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
P L A I N   L A N G U A G E   S U M M A R Y
Indomethacin for controlling internal skull pressure in adults with severe traumatic brain injury
Review question
Indomethacin (also known as indometacin) is a drug that causes vasoconstriction, that is, it makes blood vessels narrower. We were
interested in finding out how treating adults (18 years and over) with indomethacin, compared with not administering indomethacin,
aIects raised pressure inside the skull (cranium) that has been caused by a severe traumatic brain injury.
Background
Traumatic brain injury occurs when an external force injures the head. The trauma damages the brain in two diIerent phases; firstly, at
the time of impact, and then during the minutes and days following the injury, when the pressure within the skull rises (raised intracranial
pressure). This is important because raised intracranial pressure is a common cause of death and disability in people with a brain injury.
It is estimated that about 11% of people with traumatic brain injury die.
Indomethacin is a drug that some researchers think can reduce intracranial pressure, and so improve the recovery of people with traumatic
brain injury.
Search date
We searched for randomised controlled studies, which provide the most reliable evidence, up to 23 August 2019.
Study characteristics
We found that no randomised studies, either completed or ongoing, had investigated our review question.
Key results
We found no trials, either completed or ongoing, that answered our review question. Thus, this review cannot draw any conclusions about
the eIects of indomethacin on raised intracranial pressure, mortality rates, quality of life, disability or adverse eIects in adults.
Quality of the evidence
There is no evidence from randomised studies to guide healthcare professionals about the eIects (benefits or harms) of using
indomethacin to control the raised intracranial pressure that follows severe traumatic brain injury in adults. Therefore, it was not possible
to assess the quality of the evidence.
Conclusions
We are uncertain about the eIects of indomethacin in adults with severe traumatic brain injury. This absence of evidence should not be
interpreted as evidence that indomethacin does not work, but means that we did not identify eligible research for this review, and that the
eIects of indomethacin have yet to be determined by appropriately designed clinical studies.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Indomethacin for controlling intracranial hypertension secondary to severe traumatic brain injury
Indomethacin for controlling intracranial hypertension secondary to severe traumatic brain injury
Patient or population: adults presenting with elevated intracranial pressure secondary to a traumatic brain injury
Setting: emergency department
Intervention: indomethacin

















Intracranial pressure (mmHg) See comment - (0 RCTs) - No trials met the inclusion
criteria, so there are no data
for this outcome.
Mortality one month after the start of therapy See comment - (0 RCTs) - No trials met the inclusion
criteria, so there are no data
for this outcome.
Adverse effects considered as serious by either the
patient or the clinician
See comment - (0 RCTs) - No trials met the inclusion
criteria, so there are no data
for this outcome.
Disability (measured by the Glasgow Outcome Scale;
higher score is better)
See comment - (0 RCTs) - No trials met the inclusion
criteria, so there are no data
for this outcome.
Differences in quality of life (measured with a vali-
dated scale)
See comment - (0 RCTs) - No trials met the inclusion
criteria, so there are no data
for this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial
























































































































































High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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B A C K G R O U N D
Description of the condition
Traumatic brain injury (TBI), also known as intracranial injury,
occurs when an external force injures the brain. TBI can be classified
on the basis of severity, mechanism (closed or penetrating head
injury), and other features (e.g. occurring in a specific location or
over a widespread area) (Chelly 2017). Brain trauma can be caused
by a direct impact (e.g. falls, motor vehicle crashes, violence) or
by acceleration (e.g. shaking a baby). Most of these injuries are
preventable (Davanzo 2017), and prevention measures do exist.
These include the use of technology - such as seat belts and sports-
or motorcycle helmets - to protect a person during a crash, as
well as eIorts to reduce the number of motor vehicle crashes
through safety education programmes and enforcement of traIic
laws (Reilly 2007).
The damage that occurs at the time of impact is called the
primary injury. In addition, brain trauma causes secondary injury,
which is the damage that evolves over time following the trauma.
Secondary brain injury is due to a variety of events that take place in
the minutes and days following the injury. These processes, which
include alterations in cerebral blood flow and pressure within
the skull, contribute substantially to the damage caused by the
primary injury. A person's chance of recovery from head injury
depends on both the primary impact and the secondary injury
mechanisms. TBI can cause a variety of physical, cognitive, social,
emotional, and behavioural eIects. Some people can survive an
injury and experience complete recovery, while others may become
permanently disabled (Littlejohns 2005).
TBI is a frequent cause of mortality and morbidity, especially in
young adults. In western countries, injuries are the leading cause
of death in people under the age of 45 years (CDC 2015). Every
year, about 1.5 million people die in the period aPer the injury from
causes related to their original TBI, and at least 10 million people
are hospitalised as a direct result of TBI (CDC 2015). In other studies,
the annual incidence rate for hospital-treated severe TBI injury is
between 7 and 20 people per 100,000, with an average mortality
rate of about 15 per 100,000 and a case fatality rate of about 11 per
100 (Andelic 2012).
Among survivors of head injury, many people experience
permanent disability (CDC 2015). The direct costs (e.g. medical
expenses) and indirect costs (e.g. lost wages) of TBI in the USA have
been estimated to be up to USD 76.5 billion per year, according to
the Centers for Disease Control and Prevention (Bergen 2008; CDC
2015; Ponsford 2013).
Description of the intervention
Special interventions are required to minimise factors contributing
to secondary brain trauma and brain oedema (the abnormal
accumulation of water within the brain) (Donkin 2010). These
interventions include head elevation, sedation, cerebrospinal
fluid drainage, osmotic therapy (administration of hypertonic
saline to shrink cerebral tissue), barbiturates, hyperventilation,
hypothermia and indomethacin (also known as indometacin)
infusion (Meyer 2010). Indomethacin is a non-steroidal anti-
inflammatory agent with anti-inflammatory, analgesic and
antipyretic activity. Its pharmacological eIect is mediated through
inhibition of the enzyme cyclo-oxygenase, which promotes
vasoconstriction.
How the intervention might work
Refractory increases in intracranial pressure (ICP) continue to
be one of the most important causes of early death in people
with brain injury (Alarcon 2017). As the primary cerebral injury is
irreversible, the prevention of secondary injury resulting from ICP
and the promotion of adequate cerebral blood flow are important
endpoints to achieve in people with TBI (NICE 2014; Sullivan 2000).
Post-traumatic brain oedema is common and contributes to raised
ICP. Due to the limited space for volume expansion, and the need to
maintain ICP at its normal level (8 mmHg to 13 mmHg), the volume
of the brain is more eIectively controlled than that of other organs.
The control of brain volume is based on the intact blood–brain
barrier, so a disturbance of capillary permeability for small solutes
is one essential triggering mechanism behind the development
of brain oedema, according to the Lund Concept (Muzevic 2013).
This concept was introduced in 1990 to 1991 at the University
Hospital of Lund, in Sweden. It is a theoretical approach for the
treatment of severe head injury mainly based on the physiological
and pathophysiological haemodynamic principles of brain volume
and regulation of brain perfusion, and is characterised by the
treatment of ICP and maintenance of cerebral perfusion (Grände
2006). For this reason, vasoconstriction and negative fluid balances
have been used to attempt to reduce ICP in people with TBI.
Indomethacin is a potent cerebral arteriolar vasoconstrictor
that could interrupt the vicious cycle that occurs during long
ICP periods (i.e. ICP above 25 mmHg for more than seven
days) (Bratton 2007), extinguishing these waves and, ultimately,
restoring cerebral perfusion and oxygenation (Imberti 2005).
The mechanisms whereby indomethacin reduces ICP are not
fully understood, but are thought to include a decrease in
production of cerebral vasodilating prostaglandins, through cyclo-
oxygenase inhibition or regulation. Indomethacin is a non-
selective cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibitor, and
it has not yet been determined whether indomethacin primarily
inhibits cyclo-oxygenase-1 or cyclo-oxygenase-2. The cerebral
haemodynamic eIects of indomethacin are not shared by
other cyclo-oxygenase inhibitors, such as ibuprofen, diclofenac,
naproxen, or sodium salicylate (Pun 2017). This suggests
an alternative contribution to indomethacin-induced cerebral
vasoconstriction, other than inhibition of cyclo-oxygenase and
blockade of prostacyclin receptors acting directly to produce
vasoconstriction of cerebral blood vessels and reduce brain
swelling (Godoy 2017). Alternatively, indomethacin may have a
direct neuroprotective eIect that is shown aPer non-selective
cyclo-oxygenase inhibition (Girgis 2013). These eIects may be
due to a non-prostaglandin-mediated mechanism that interferes
directly with the regulation of cerebrovascular tone, mediated by
extracellular pH (Girgis 2013).
Since indomethacin acts as a cerebral precapillary vasoconstrictor,
it has also been studied in people with head injuries. DiIerent
studies demonstrated that indomethacin can decrease ICP and
improve cerebral perfusion pressure (CPP) in people with refractory
ICP who demonstrate no response to other or classic therapies
(Godoy 2012; Rasmussen 2004).
Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults (Review)
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The use of indomethacin in treating raised ICP secondary to
TBI is controversial. Clinical studies suggest that it may be
useful in the management of intracranial hypertension, when
used in combination with standard techniques, by decreasing
cerebral blood flow and reducing ICP during the restoration of
the blood-brain barrier (Smirl 2014). Data from animal models
and randomised controlled studies with preterm infants have
shown that intravenous indomethacin produces rapid, significant
reductions in cerebral blood flow (El-Mashad 2017). Controlled
studies in healthy volunteers showed a reduction in cerebral blood
flow (NCT01280006). Case series involving people with severe TBI
suggest that indomethacin boluses of 30 mg to 50 mg reduce ICP
by 37% to 52%, reduce cerebral blood flow by 26%, and cause a
modest 14% increase in CPP (Godoy 2017). There are questions
about possible cerebral ischaemia, since indomethacin causes
vasoconstriction. However, there is no evidence that indomethacin
causes ischaemic damage from examination using diIusion-
weighted magnetic resonance imaging (MRI) (Biestro 1995; Godoy
2005).
Indomethacin can produce side eIects in a minority of patients
(less than 10%). In those aIected, transient renal insuIiciency,
jaundice, elevated liver function test values and headache occur
more frequently than dizziness, dyspepsia, nausea and other
upper gastrointestinal symptoms. Very infrequently it can cause
acute respiratory distress and congestive heart failure (Medscape
monograph 2019), which can be fatal.
Why it is important to do this review
To date, experimental and clinical studies suggest a beneficial eIect
from the use of indomethacin in adults with uncontrolled ICP, but
its use is still controversial. A systematic review will clarify the
evidence in relation to this important issue.
O B J E C T I V E S
To assess the eIects of indomethacin for people with severe
traumatic brain injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included  adults (≥  18 years old) presenting with severe
traumatic brain injury (defined as having an initial Glasgow Coma
Scale (GCS) score of < 8) (Jennett 1975), due to any cause,
and associated with elevated intracranial pressure (ICP) (> 20
mmHg), with no previous decompressive surgery, despite other
comorbidities.
Types of interventions
We assessed indomethacin compared with any control group,
making sure that the comparison allowed the determination of the
specific eIects of indomethacin (that is, the use of indomethacin
must have been the only diIerence between the intervention and
control study arms). The intervention could have been given to
participants for any length of time. Indomethacin is normally given
by an intravenous loading dose followed by an infusion. In this
review, any route of administration was acceptable.
Types of outcome measures
We considered all the following outcomes for the Summary of
findings for the main comparison.
Primary outcomes
1. ICP (mmHg) (measured by an epidural, subdural
or intraparenchymatous brain catheter with continuous
monitoring). We planned to group ICP values measured at
similar time points across studies.
Secondary outcomes
1. Mortality (measured at approximately one month aPer the start
of therapy).
2. Adverse eIects considered to be serious by either the patient or
the clinician.
3. Disability, measured by the Glasgow Outcome Scale (GOS)
(Jennett 1975), or any other measures of neurological
functioning or disability, six months aPer the start of therapy.
4. DiIerences in quality of life (measured with a validated scale,
such as the 36-Item Short Form Health Survey (SF-36) (Ware
1992), or the Davidson Trauma Scale (DTS) (Davidson 1997), six
months aPer the start of therapy.
Search methods for identification of studies
In order to reduce publication and retrieval bias, we did not restrict
our search by language, date or publication status.
Electronic searches
The Cochrane Injuries Group's Information Specialist ran our
preliminary searches in April 2018, including one database that was
not searched later:
1. Institute for Scientific Information (ISI) Web of Science: Science
Citation Index Expanded (SCI-EXPANDED) (1970 to 30 April 2018).
Then Jane Falconer, Librarian at the London School of Hygiene
& Tropical Medicine, searched the following sources on 23 August
2019:
1. Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 8) in the Cochrane Library (23 August 2019);
2. OvidSP Medline and Epub Ahead of Print, In-Process & Other
Non-Indexed Citations and Daily, 1946 to 22 August 2019;
3. OvidSP Embase Classic + Embase, 1947 to 22 August 2019;
4. Ebsco CINAHL Plus, complete database (23 August 2019);
5. LILACS (Latin American and Caribbean Health Science
Information database; 1982 to 23 August 2018);
6. OpenGrey for grey literature (www.opengrey.eu) (accessed 23
August 2019);
7. Web of Science Core Collection databases, data last updated 21
August 2019;
a. Science Citation Index Expanded (SCI-EXPANDED), 1970
onwards (accessed 23 August 2019);
b. Conference Proceedings Citation Index - Science (CPCI-S),
1990 onwards (accessed 23 August 2019);
Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults (Review)
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8. trials registers:
a. World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) search portal (apps.who.int/
trialsearch) (accessed 23 August 2019);
b. ClinicalTrials.gov (clinicaltrials.gov) (accessed 23 August
2019).
We adapted the MEDLINE search strategy (Appendix 1) as necessary
for each of the other databases. The added study filter was a
modified version of the Ovid MEDLINE Cochrane Highly Sensitive
Search Strategy for identifying randomised trials. For the Embase
search strategy, we added the study design terms as used by the UK
Cochrane Centre (Lefebvre 2011).
Searching other resources
We handsearched the following conference proceedings.
1. Proceedings of the Intensive Care Society and Riverside Group
(London) (1997, 1998, 2001, 2002 and 2003).
2. Congreso Argentino de Terapia Intensiva (2001 to 2017, except
2002 and 2005, as conferences were not held in those years).
We checked the reference lists of relevant studies (narrative reviews
and systematic reviews). We also contacted the Intensive Care
Society and Riverside Group to request proceedings that were not
available online.
Data collection and analysis
Selection of studies
At least two authors (Carlos Martín Saborido (CMS), Fernado G
Baccaro (FB), Agustín Ciapponi (AC), Elena Garcia (EG), Gema
Escobar (GE), Carlos Enrique Sánchez Martín (CESM) and Carolina
Palermo (CP) ) independently screened titles and abstracts. At least
two review authors (CMS, FB, AC, GE, CESM, and CP) independently
assessed full-text articles of potentially eligible studies. If there
was no consensus between the two authors involved in the
screening or in the assessment of the full-texts, Jesús López
Alcalde (JLA) intervened to solve the disagreement. We used
Covidence to implement the selection process (Covidence 2017).
We documented the reasons for the exclusion of the full-text
articles we assessed.
Data extraction and management
We could not extract data because we did not find any relevant
studies. For each included study, we had planned to extract details
of the population, setting, methods, intervention and comparator,
outcomes, funding, and declaration of interests. We had also
planned to populate a table of ‘Characteristics of included studies’
and to look for retraction statements regarding each included
study.
Assessment of risk of bias in included studies
We could not assess risk of bias because we did not find any
relevant studies. We had intended that two review authors would
independently assess risk of bias for each study using the criteria
outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a). We had planned to resolve any
disagreements by discussion or by involving another review author.
Measures of treatment e9ect
For continuous data, we had planned to compare the values in the
treatment and control groups at final follow-up. We had expected
to use mean diIerences (MDs) with 95% confidence intervals (CIs)
as summary statistics. If studies had used diIerent measurement
instruments or units to measure an outcome, we had planned to
use the standardised mean diIerence (SMD).
If dichotomous data had been presented, we would have calculated
risk ratios (RR) with 95% CIs. Additionally, we would have
transformed the GOS and GCS data into the dichotomous outcomes
of 'favourable' (moderate disability, good recovery; GOS 4 and 5)
and 'unfavourable' (death, vegetative state, severe disability; GOS
1 to 3) (Brazinova 2010; Jennett 1975).
If some studies had reported an outcome as a dichotomous
measure and others had used a continuous measure of the same
construct, we would have converted results from a RR to a
SMD, provided that we could have assumed that the underlying
continuous measure had an approximately normal distribution.
Unit of analysis issues
The unit of analysis would have been the person with severe brain
trauma. If we had included cluster-RCTs in the analysis, we had
planned to reanalyse these studies by calculating their sample
size with an estimate of the intracluster coeIicient (ICC), which we
would have estimated from similar studies if the ICC had not been
given (Higgins 2011b).
Dealing with missing data
Where necessary, we had planned to contact the corresponding
authors of included studies up to three times to request unreported
data.
If studies had not reported the standard deviation (SD), we had
planned to calculate it from P values, t values, CIs, or standard
errors (Higgins 2011c). If this information had not been reported, or
was unavailable, we would have borrowed the SD from the study
with the highest SD for that outcome. To assess the eIect of missing
data on the analysis, we had planned to conduct a sensitivity
analysis for that outcome by showing our results with the borrowed
SD versus the lowest SD.
If outcome data had been reported only as a median or range, we
would have reported the information in additional tables.
If a study had reported outcomes only for the participants who
completed the trial, or only for participants who followed the
protocol, we would have asked the study authors to provide
additional information to allow us to conduct meta-analyses using
the intention-to-treat approach. We would have described missing
data and dropouts for each included study in the 'Risk of bias' table,
reporting the reasons, number, and characteristics of dropouts.
Also, we would have discussed the extent to which the missing
data could have altered the results. We had planned to conduct
sensitivity analyses to assess the eIect of missing dichotomous
data on our primary meta-analysis, by assuming firstly that all
missing data were successes, and secondly that all missing data
were failures (best- versus worst-case scenario analyses).
Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults (Review)
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We had expected to impute the missing data with replacement
values, and to treat them as they were observed (last observation
carried forward (LOCF) or imputing the mean). If levels of missing
data in a study had been very high (e.g. 80%), we would not have
included that study in the analysis.
We had planned to explore the impact of including studies with
missing data in the overall assessment of the treatment eIect by
using 'worst-case' and 'best-case' scenario sensitivity analyses. We
would have addressed the potential impact of missing data on the
findings of the review in the discussion section.
Assessment of heterogeneity
We could not assess heterogeneity because we did not find any
studies. We had planned to explore clinical and statistical sources
of heterogeneity among the studies (Deeks 2011). Clinical sources
could have included comorbidity, brain injury severity, and type of
indomethacin administration protocols. We would have assessed
statistical heterogeneity using the I2 statistic and the Chi2 test. We
would have considered a result to be statistically significant if P
< 0.1. We had planned to consider values of I2 over 60% to be
an indication of 'moderate' heterogeneity and values above 85%
to represent 'considerable' heterogeneity. We had planned not to
carry out a meta-analysis if I2 was considerable, and would have
documented the rationale for our decision.
Assessment of reporting biases
We could not assess reporting bias because we did not find any
studies. If we had included at least 10 studies in the analysis, we
had planned to create a funnel plot. Funnel plot asymmetry can be
due to publication bias, but it can also be due to a real relationship
between trial size and eIect size, such as when larger trials have
lower compliance and compliance is positively related to eIect size.
In general, asymmetry may be due to selection biases (publication
bias, delayed publication bias, location biases, selective outcome
reporting), poor methodological quality leading to spuriously
inflated eIects in smaller studies (poor methodological design,
inadequate analysis, fraud), true heterogeneity or chance (Egger
1997). We had planned to use the test proposed by Egger 1997 to
test for funnel plot asymmetry (Sterne 2011).
Data synthesis
We could not perform data synthesis because we did not find any
studies. If we had found at least two studies that were suIiciently
homogenous in terms of participants, interventions and outcomes,
we had planned to synthesise results in a meta-analysis. We would
have performed statistical analysis using the Cochrane soPware,
Review Manager (Review Manager 2014). Because we had assumed
that clinical heterogeneity was very likely to impact on the results
of our review, given the nature of the intervention included, we had
planned to report results from the random-eIects model.
Subgroup analysis and investigation of heterogeneity
We could not perform subgroup analysis or investigate
heterogeneity because we did not find any studies.
In the protocol for this review, we had planned to conduct subgroup
analyses classifying the trials as follows:
1. severity of traumatic brain injury (mild and moderate (GCS 9 to
15) versus severe (GCS 3 to 8));
2. comorbidity (severe comorbidity versus non-severe
comorbidity);
3. diIerent indomethacin administration protocols.
Sensitivity analysis
We could not perform sensitivity analysis because we did not find
any studies.
At the protocol stage, we had planned to conduct sensitivity
analyses to assess the impact of the following factors on the results
of the primary analyses:
1. risk of bias (allocation concealment and sequence generation):
we had planned to restrict the analysis to only studies with low
risk of selection bias;
2. missing participant data: we had planned to explore the impact
of including studies with high levels of missing data.
R E S U L T S
Description of studies
Results of the search
Electronic searches yielded 8648 records aPer removal of
duplicates. We examined titles and abstracts and retrieved 21
full-text articles for further examination. We did not identify any
studies that met the eligibility criteria. We did not find any further
eligible studies, either complete or ongoing, through searching
other sources (checking the abstracts of relevant conferences, and
checking reference lists of key documents). We did not identify
any ongoing trials. The study flow diagram (Figure 1) follows the
template described in the PRISMA statement (Liberati 2009).
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Figure 1.   Study flow diagram
 
Included studies
We found no eligible studies for this review.
Excluded studies
We excluded all 21 records that we retrieved for full-text assessment
of eligibility. We summarised the reasons for their exclusion in
the flow diagram (Figure 1) and in the Characteristics of excluded
studies table. The most frequent reason for exclusion of potentially
relevant studies was the absence of randomisation (the most
frequent design was the uncontrolled before-aPer study) (Biestro
1995; Blaser 1988; Clemmesen 1997; Dahl 1996; Dohi 2006; Godoy
2012; Godoy 2014; Imberti 2005; Jensen 1990; Jensen 1991; Jensen
1992; Muehlschlegel 2013; Nitter 1995; Puppo 2007).
Risk of bias in included studies
No studies met the eligibility criteria, so we could not assess risk of
bias.
E9ects of interventions
See: Summary of findings for the main comparison
Indomethacin for controlling intracranial hypertension secondary
to severe traumatic brain injury
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We did not find any trials that assessed the eIects of indomethacin
in controlling intracranial hypertension secondary to severe TBI.
D I S C U S S I O N
Summary of main results
This review did not find any eligible studies, either completed
or ongoing. Consequently, we could not determine the eIects of
indomethacin in controlling intracranial hypertension secondary to
severe traumatic brain injury (TBI).
Overall completeness and applicability of evidence
Completeness of the evidence
No trials met our inclusion criteria. Thus, the evidence base for
the eIects of indomethacin in controlling intracranial hypertension
secondary to severe TBI is incomplete. Although electronic
searches retrieved a considerable number of records, none of the
studies identified met the inclusion criteria because most had a
controlled before-aPer study design.
It is possible that the setting of our research question (emergency
departments) might mean that trialists would not choose RCTs as
their preferred design, and this could explain why we found several
uncontrolled before-aPer studies.
Applicability of the evidence
We could not assess the applicability of the evidence of this review
as we did not find any eligible studies.
Quality of the evidence
We identified no eligible studies for this review. Thus, we were
unable to comment on the quality of the evidence for this clinical
question.
Potential biases in the review process
Our searches were extensive in order to reduce the risk of
publication bias and to identify as much relevant evidence as
possible. Our searches were carefully designed by the Information
Specialist of the Cochrane Injuries Group and the Librarian at
the London School of Hygiene & Tropical Medicine, without any
restrictions on language or date of publication. However, we did not
contact pharmaceutical companies, which might have identified
potentially eligible study data that were unpublished. We could
not screen all conference proceedings for the Proceedings of the
Intensive Care Society and Riverside Group as they were not
available through their website. Similarly, conference proceedings
for the Congreso Argentino de Terapia Intensiva were only available
for the years 2001 to 2017 (except 2002 and 2005, as conferences
were not held in those years).
Agreements and disagreements with other studies or
reviews
We found no randomised studies conducted on this topic, but we
did find a review that assessed the use of indomethacin and its
eIects on intracranial pressure (ICP) in patients with neurological
illness (Sader 2015). This review defined eligible studies as being
prospective, with five or more participants who had a documented
response to indomethacin, and with trial reports published in
English. Its authors identified two RCTs where the participants
had brain tumours but not TBI, and 10 prospective cohort studies
investigating people with TBI. Sader 2015 stated that nine out
of 10 studies documented a decrease in ICP with indomethacin
administration, and concluded that evidence provided by these
studies suggested that indomethacin may reduce ICP in the severe
TBI population. However, studies which did not show an eIect
of indomethacin on ICP were not eligible for inclusion in the
review, so indomethacin for ICP control remains experimental and
further prospective studies are needed (Sader 2015). Only two
studies included in the Sader 2015 review reported adverse events
related to indomethacin administration: one was a study of people
with severe TBI, where there was a critical reduction in jugular
venous oxygen saturation in two of the six patients treated with
indomethacin; and the other was a study of idiopathic intracranial
hypertension which described dizziness in four patients.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found no randomised controlled trials (RCTs), either completed
or ongoing, that assessed the eIects of indomethacin in controlling
intracranial hypertension secondary to severe traumatic brain
injury (TBI). Thus, we could not draw conclusions about the impact
of indomethacin on intracranial pressure, mortality rates, quality of
life, disability or adverse eIects.
This absence of evidence should not be interpreted as evidence of
no eIect for indomethacin in controlling intracranial hypertension
secondary to severe TBI. It means that we did not identify any
evidence from RCTs which could inform practice.
Implications for research
This is an 'empty review', that is, a review that has found no eligible
studies for inclusion. This highlights the need for rigorous RCTs to
determine the eIects of indomethacin in controlling intracranial
hypertension secondary to severe TBI.
Future trials should be rigorous in design and delivery. Researchers
should report the trial according to relevant guidelines, such
as CONSORT (CONsolidated Standards of Reporting Trials 2010)
(Schulz 2010), TIDieR (template for intervention description and
replication) (HoImann 2014), and reporting guidelines for health
equity concerns in RCTs (Welch 2017).
The RCT should evaluate the eIect of indomethacin on patient-
relevant outcomes. To our knowledge there is no 'core outcome
set' (COS) for RCTs in this area. A COS should be developed with
the methodology proposed in the COMET Handbook (Williamson
2017).
A rigorous evaluation of indomethacin is required to evaluate
benefits and harms in patients with TBI. The evaluation of harms
will require an adequately powered study.
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Fan 2010 Participants did not have TBI, but were healthy adults
Fan 2011 Participants did not have TBI, but were healthy adults
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Appendix 1. Search strategies
Wiley Cochrane Central Register of Controlled Trials
#1 MeSH descriptor: [Indomethacin] explode all trees (2514)









#11 #1 or #2 or #3 or #4 or #5 or #6 or #9 or #10 (31613)
#12 MeSH descriptor: [Brain Ischemia] explode all trees (3230)
#13 MeSH descriptor: [Intracranial Pressure] this term only (335)
#14 MeSH descriptor: [Cerebrovascular Circulation] explode all trees (1525)
#15 MeSH descriptor: [Brain Edema] this term only (185)
#16 MeSH descriptor: [Intracranial Hypertension] explode all trees (180)
#17 MeSH descriptor: [Craniocerebral Trauma] explode all trees (3134)
#18 MeSH descriptor: [Decompression, Surgical] this term only (482)
#19 MeSH descriptor: [Decompressive Craniectomy] this term only (20)
#20 MeSH descriptor: [Monitoring, Physiologic] this term only (2152)
#21 MeSH descriptor: [Hemodynamic Monitoring] this term only (9)
#22 MeSH descriptor: [Monitoring, Intraoperative] explode all trees (1556)
#23 MeSH descriptor: [Neurophysiological Monitoring] explode all trees (44)
#24 ((intracranial or cerebr* or brain) near/3 hypertens*):ti,ab,kw (977)
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#25 (brain near/3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP)):ti,ab,kw (12455)
#26 ((cerebral or intracranial) near/3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP or
vasoconstrict*)):ti,ab,kw (4251)
#27 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 (22566)
#28 #11 and #27 (344)
OvidSP Medline and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily
1 exp Indomethacin/ (29933)









11 or/1-10 [INDOMETHACIN] (225782)
12 exp Brain Ischemia/ (103084)
13 Intracranial Pressure/ (14699)
14 exp Cerebrovascular Circulation/ (53866)
15 Brain Edema/ (14186)
16 exp Intracranial Hypertension/ (9610)
17 exp Craniocerebral Trauma/ (152505)
18 decompression, surgical/ (14782)
19 decompressive craniectomy/ (1202)
20 monitoring, physiologic/ (53061)
21 hemodynamic monitoring/ (127)
22 exp monitoring, intraoperative/ (19246)
23 exp neurophysiological monitoring/ (1307)
24 ((intracranial or cerebr* or brain) adj3 hypertens*).ab,ti. (10713)
25 (brain adj3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP)).ab,ti. (85746)
26 ((cerebral or intracranial) adj3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP or
vasoconstrict*)).ab,ti. (68725)
27 or/12-26 [INTRACRANIAL HYPERTENSION] (452198)
28 randomi?ed.ab,ti. (582266)
29 randomized controlled trial.pt. (487883)
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30 controlled clinical trial.pt. (93234)
31 placebo.ab. (200192)
32 exp Clinical Trials as Topic/ (329437)
33 randomly.ab. (316700)
34 trial.ti. (203504)
35 comparative study/ (1838023)
36 or/28-35 [RANDOMISED CONTROLLED TRIALS] (2940717)
37 11 and 27 and 36 (650)
38 remove duplicates from 37 (649)
39 limit 38 to medline (604)
40 38 not 39 (45)
OvidSP Embase Classic + Embase
1 indometacin/ (78844)










12 exp brain ischemia/ (177720)
13 intracranial pressure/ (24357)
14 exp brain circulation/ (24488)
15 brain edema/ (33389)
16 exp intracranial hypertension/ (19707)
17 head injury/ (52449)
18 exp brain injury/ (182521)
19 second impact syndrome/ (148)
20 exp skull injury/ (30094)
21 decompression surgery/ (18338)
22 brain decompression/ (2037)
23 decompressive craniectomy/ (3589)
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24 exp physiologic monitoring/ (5795)
25 hemodynamic monitoring/ (15388)
26 exp intraoperative monitoring/ (1783)
27 ((intracranial or cerebr* or brain) adj3 hypertens*).ab,ti. (16283)
28 (brain adj3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP)).ab,ti. (123234)
29 ((cerebral or intracranial) adj3 (isch?emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP or
vasoconstrict*)).ab,ti. (98796)
30 or/12-29 (568932)
31 exp controlled study/ (7062015)
32 comparative study/ (854995)
33 randomi?ed.ab,ti. (837883)
34 placebo.ab. (289971)
35 *Clinical Trial/ (19136)
36 major clinical study/ (3551322)
37 randomly.ab. (421716)
38 (trial or study).ti. (1953943)
39 or/31-38 (10935050)
40 (animals not (humans and animals)).sh. (374)
41 39 not 40 (10935022)
42 11 and 30 and 41 (3574)
43 remove duplicates from 42 (3519)
Ebsco CINAHL Plus
S1 (MH "Indomethacin") (1,220)
S2 (MH "Antiinflammatory Agents, Non-Steroidal") (12,430)
S3 (TI indomethacin*) OR (AB indomethacin*) (1,642)
S4 (TI indometacin*) OR (AB indometacin*) (36)
S5 (TI ketorolac) OR (AB ketorolac) (687)
S6 (TI IDM) OR (AB IDM) (144)
S7 (TI indocin) OR (AB indocin) (4)
S8 (TI indocid) OR (AB indocid) (2)
S9 (TI tivorbex) OR (AB tivorbex) (2)
S10 (TI nsaid#) OR (AB nsaid#) (4,973)
S11 (TI anti-inflammator*) OR (AB anti-inflammator*) (19,533)
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 (31,941)
S13 (MH "Cerebral Ischemia+") (16,005)
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S14 (MH "Intracranial Pressure") (2,248)
S15 (MH "Cerebrovascular Circulation") (7,155)
S16 (MH "Cerebral Edema+") (1,739)
S17 (MH "Intracranial Hypertension+") (4,489)
S18 (MH "Head Injuries") (6,683)
S19 (MH "Brain Injuries+") (25,977)
S20 (MH "Skull Fractures+") (2,292)
S21 (MH "Decompression, Surgical") (452)
S22 (MH "Decompressive Craniectomy") (169)
S23 (MH "Monitoring, Physiologic") (18,857)
S24 (MH "Intraoperative Monitoring") (4,717)
S25 (MH "Monitoring, Intracranial Pressure") (241)
S26 (TI (intracranial or cerebr* or brain) N3 hypertens*) OR (AB (intracranial or cerebr* or brain) N3 hypertens*) (1,891)
S27 (TI brain N3 (isch#emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP)) OR (AB brain N3 (isch#emia
or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP)) (25,287)
S28 (TI (cerebral or intracranial) N3 (isch#emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP or CPP or
vasoconstrict*)) OR (AB (cerebral or intracranial) N3 (isch#emia or pressure or perfusion or oedema or edema or injur* or trauma* or ICP
or CPP or vasoconstrict*)) (10,765)
S29 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 (98,242)
S30 (TI randomi?ed) OR (AB randomi?ed) (207,768)
S31 (AB placebo) (47,411)
S32 (AB randomly) (75,765)
S33 (TI trial) (94,043)
S34 (MH "Clinical Trials+") (265,240)
S35 S30 OR S31 OR S32 OR S33 OR S34 (412,061)
S36 S12 AND S29 Limiters - Publication Type: Randomized Controlled Trial (16)
S37 S12 AND S29 AND S35 (101)
S38 S36 OR S37 (10)
Clarivate Analytics Web of Science
#1 TOPIC: (indometacin or indomethacin or indometacina or indometacine or indometacinum or indocin or indocid or tivorbex or nsaid
$ or "anti-inflammator*") (183428)
#2 TOPIC: (((intracranial or cerebr* or brain) near/3 hypertens*) or (brain near/3 (isch$emia or pressure or perfusion or oedema or edema
or injur* or trauma* or ICP or CPP)) or ((cerebral or intracranial) near/3 (isch$emia or pressure or perfusion or oedema or edema or injur*
or trauma* or ICP or CPP or vasoconstrict*))) (188343)
#3 TOPIC: (randomi?ed or placebo or randomly or trial) (1908463)
#4 #1 AND #2 AND #3 (598)
All searches run on Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
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VHL LILACS
(tw:(indometacin$ OR indomethacin$ OR indocin OR indocid OR tivorbex OR ketorolac OR idm OR nsaid OR nsaids OR anti-inflammator$))
AND (tw:((intracranial AND hypertens$) OR (cerebr$ AND hypertens$) OR (brain AND hypertens$) OR (brain AND ischaemia) OR (brain AND
ischemia) OR (brain AND pressure) OR (brain AND perfusion) OR (brain AND oedema) OR (brain AND edema) OR (brain AND injur$) OR (brain
AND trauma$) OR (brain AND ICP) OR (brain AND CPP) OR (cerebral AND ischaemia) OR (cerebral AND ischemia) OR (cerebral AND pressure)
OR (cerebral AND perfusion) OR (cerebral AND oedema) OR (cerebral AND edema) OR (cerebral AND injur$) OR (cerebral AND trauma$) OR
(cerebral AND ICP) OR (cerebral AND CPP) OR (cerebral AND vasoconstrict$) OR (intracranial AND ischaemia) OR (intracranial AND ischemia)
OR (intracranial AND pressure) OR (intracranial AND perfusion) OR (intracranial AND oedema) OR (intracranial AND edema) OR (intracranial
AND injur$) OR (intracranial AND trauma$) OR (intracranial AND ICP) OR (intracranial AND CPP) OR (intracranial AND vasoconstrict$))) AND
(tw:(randomised OR randomized OR placebo OR randomly OR trial))
OpenGrey
(indomethacin* OR indometacin* OR indocin or indocid or tivorbex or ketorolac or IDM or nsaid or nsaids) AND ((intracranial AND hypertens)
OR (cerebr* AND hypertens*) OR (brain AND hypertens*) OR (brain AND ischaemia) OR (brain AND ischemia) OR (brain AND pressure) OR
(brain AND perfusion) OR (brain AND oedema) OR (brain AND edema) OR (brain AND injur*) OR (brain AND trauma*) OR (brain AND ICP)
OR (brain AND CPP) OR (cerebral AND ischaemia) OR (cerebral AND ischemia) OR (cerebral AND pressure) OR (cerebral AND perfusion) OR
(cerebral AND oedema) OR (cerebral AND edema) OR (cerebral AND injur*) OR (cerebral AND trauma*) OR (cerebral AND ICP) OR (cerebral
AND CPP) OR (cerebral AND vasoconstrict*) OR (intracranial AND ischaemia) OR (intracranial AND ischemia) OR (intracranial AND pressure)
OR (intracranial AND perfusion) OR (intracranial AND oedema) OR (intracranial AND edema) OR (intracranial AND injur*) OR (intracranial
AND trauma*) OR (intracranial AND ICP) OR (intracranial AND CPP) OR (intracranial AND vasoconstrict*))
World Health Organization International Clinical Trials Registry Platform
Condition: intracranial or cerebr* or brain
Intervention: indomethacin* OR indometacin*
Clinicaltrials.gov
Condition: intracranial or cerebr* or brain
Intervention: indomethacin* OR indometacin*
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  CMS JLA AC CESM EG GE MCP FB
Piloted procedures for the selection of studies X X            
Screened titles and abstracts and assessed full texts X   X X X X X X
Assessed conference abstracts X   X X X X X X
Entered data into RevMan; data analysis; checked data en-
tered into RevMan
X X            
Wrote the background section             X X
Wrote the methodological sections of the review X X X       X X
Wrote the results, discussion and conclusions sections X X            
Prepared the flow-chart X X            
Prepared 'Summary of findings' tables X X            
Made an intellectual contribution and provided the clinical
perspective
  X   X     X X
Edited the review X X X X X X X X
Assessed MECIR standards X X            
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Search methods
We handsearched the conference proceedings for the Argentine Society of Intensive Therapy (SATI) from 2001 rather than from 1990, as
the proceedings from 1990 to 2001 were not available. With regard to the proceedings of the Intensive Care Society and Riverside Group,
we identified some volumes through the website (1997, 1998, 2001, 2002 and 2003). We wrote to the Riverside Group twice requesting the
remaining volumes, but we had not received an answer at the time of finishing this review.
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